In Vivo Formation of 8-Iso-Prostaglandin F2α and Platelet Activation in Diabetes Mellitus
暂无分享,去创建一个
G. Davı̀ | C. Patrono | T. Bucciarelli | F. Capani | A. Consoli | S. Santarone | G. Ciabattoni | A. Falco | F. Costantini | A. Mezzetti | E. Vitacolonna | E. Pennese
[1] G. Davı̀,et al. Antiplatelet agents in the prevention of diabetic vascular complications. , 1993, Diabetes/metabolism reviews.
[2] J. Morrow,et al. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. , 1992, Prostaglandins.
[3] G. Davı̀,et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. , 1997, Circulation.
[4] G. FitzGerald,et al. Local Amplification of Platelet Function by 8-Epi Prostaglandin F2α Is Not Mediated by Thromboxane Receptor Isoforms* , 1996, The Journal of Biological Chemistry.
[5] J. Morrow,et al. Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. , 1992, The Journal of clinical investigation.
[6] B. Halliwell,et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM , 1997, Diabetologia.
[7] D. Betteridge,et al. Plasma 8‐epi‐PGF2α levels are elevated in individuals with non‐insulin dependent diabetes mellitus , 1995, FEBS letters.
[8] A. Jenkins,et al. LDL From Patients With Well-Controlled IDDM Is Not More Susceptible to In Vitro Oxidation , 1996, Diabetes.
[9] G. Davı̀,et al. In Vivo Formation of 8-Epi-Prostaglandin F2α Is Increased in Hypercholesterolemia , 1997 .
[10] A. Manto,et al. Defective Plasma Antioxidant Defenses and Enhanced Susceptibility to Lipid Peroxidation in Uncomplicated IDDM , 1997, Diabetes.
[11] P. Halushka,et al. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets. , 1994, The Journal of pharmacology and experimental therapeutics.
[12] J. Berliner,et al. The role of oxidized lipoproteins in atherogenesis. , 1996, Free radical biology & medicine.
[13] I. Hirsch,et al. Reduced Plasma Peroxyl Radical Trapping Capacity and Increased Susceptibility of LDL to Oxidation In Poorly Controlled IDDM , 1994, Diabetes.
[14] J. Morrow,et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[15] U. Garbin,et al. E-Selectin plasma concentration is influenced by glycaemic control in NIDDM patients: possible role of oxidative stress , 1997, Diabetologia.
[16] G. FitzGerald,et al. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[17] G. FitzGerald,et al. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. , 1995, The Journal of pharmacology and experimental therapeutics.
[18] P. Koudstaal,et al. Platelet activation and lipid peroxidation in patients with acute ischemic stroke. , 1997, Stroke.
[19] G. Davı̀,et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. , 1990, The New England journal of medicine.
[20] C. Patrono,et al. Eicosanoids and Iso-Eicosanoids: Constitutive, Inducible and Transcellular Biosynthesis in Vascular Disease , 1998, Thrombosis and Haemostasis.
[21] J. Morrow,et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. , 1995, The New England journal of medicine.
[22] A. de Leiva,et al. Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control , 1996, Diabetologia.
[23] A. Lechi,et al. The F2-isoprostane 8-epiprostaglandin F2alpha increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[24] M. Reilly,et al. Modulation of oxidant stress in vivo in chronic cigarette smokers. , 1996, Circulation.
[25] J. Morrow,et al. Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. , 1993, The Journal of biological chemistry.
[26] L. Lanting,et al. Formation of an F2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors. , 1996, The American journal of physiology.
[27] G. FitzGerald,et al. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. , 1987, Biochimica et biophysica acta.
[28] T. Ishikawa,et al. Vitamin E/lipid peroxide ratio and susceptibility of LDL to oxidative modification in non-insulin-dependent diabetes mellitus. , 1997, Arteriosclerosis, thrombosis, and vascular biology.